The role of inflammation in cardiovascular diseases: the predictive value of neutrophil–lymphocyte ratio as a marker in peripheral arterial disease

Feliciano Chanana Paquissi
Department of Medicine, Clínica Girassol, Luanda, Angola

Abstract: Peripheral arterial disease (PAD) is an important manifestation of atherosclerosis, with increasing prevalence worldwide. A growing body of evidence shows that the systemic inflammatory response is closely related to the development, progression, and prognosis of atherosclerosis. In the last decade, several studies have suggested the role of measured inflammatory biomarkers as predictors of severity and prognosis in PAD in an effort to stratify the risk of these patients, to improve treatment selection, and to predict the results after interventions. A simple inflammatory marker, more available than any other, is the neutrophil–lymphocyte ratio (NLR), which can be easily obtained in clinical practice, based on the absolute count of neutrophils and lymphocytes from the differential leukocytes count. Many researchers evaluated vigorously the NLR as a potential prognostic biomarker predicting pathological and survival outcomes in patients with atherosclerosis. In this work, we aim to present the role of NLR as a prognostic marker in patients with PAD through a thorough review of the literature.

Keywords: neutrophil–lymphocyte ratio, peripheral arterial disease, inflammation, cardiovascular diseases, biomarkers

Introduction
Peripheral arterial disease (PAD) is an important manifestation of atherosclerosis, which affects >202 million people worldwide, and is associated with cardiovascular events, with increased all-cause and cardiovascular mortality. PAD, despite the advances registered in its treatment, still has a worse prognosis compared with coronary artery disease (CAD) by various factors, including the high rate of in-stent restenosis, which occurs with an important contribution of the inflammatory response. These negative outcomes have brought in sight the need of biomarkers as predictors of outcomes to ensure better risk stratification, proper selection of treatment approaches, and, if necessary, additional multitarget approaches (such as the endovascular brachytherapy). In recent years, the literature has highlighted the value of systemic inflammation as an important element in the development, progression, and prognosis of atherosclerosis. It is worth to mention that PAD is the atherosclerotic manifestation that shows the greater relationship with systemic inflammation. Several inflammatory markers have been shown to be useful in clinical studies on risk stratification and prognosis of patients with PAD, as well as in those with disease in other vascular beds as cerebral and coronary.
Among the inflammatory markers, neutrophil–lymphocyte ratio (NLR), defined as the ratio of absolute counts of neutrophils and lymphocytes, has gained space as an effective biomarker in the stratification and prognosis of atherosclerotic cardiovascular disease (CVD), and in particular PAD. The NLR is a derived marker, simple, relatively inexpensive, more available than any other, and has shown itself to be a good predictor for other multiple cardiovascular outcomes that reflect an imbalance in the inflammatory cells and the role of activated neutrophils in atherogenesis.

In a representative sample from the National Health and Nutrition Examination Survey, including 9,427 subjects, the average NLR was 2.15 in the general population, being significantly higher in subjects who reported diabetes, CVD, and smoking than in those who did not.

In this article, we reviewed the clinical studies that evaluated the role of inflammatory biomarkers as predictors of outcomes in patients with PAD, with particular emphasis on NLR.

**Prognostic value of inflammatory biomarkers in CVDs in general**

Multiple inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) have been associated with cardiovascular events. CRP is associated with CAD, ischemic stroke, and mortality by vascular and nonvascular causes.

**The NLR as a biomarker in CAD**

On CAD, a high NLR is associated with severity of disease, as was evident in a cohort of 3,005 patients undergoing coronary angiography for several indications, in which those with NLR >3 had more advanced obstructive CAD (odds ratio [OR] 2.45, \( P<0.001 \)) and worse prognosis, with higher rates of major cardiovascular events (hazard ratio [HR] 1.55, \( P=0.01 \)) within 3 years of follow-up. NLR is a predictor of mortality in patients with ischemic heart disease both in stable CAD and in acute coronary syndrome. A high NLR at admission for acute coronary syndrome is associated with all-cause in-hospital (OR 2.04, \( P=0.013 \)) and 6-month mortality (OR 3.88, \( P<0.001 \)). In treated patients, a high pre-intervention NLR was an independent predictor of in-stent restenosis after percutaneous coronary intervention (OR 1.85, \( P<0.001 \)). Saphenous vein graft failure for those undergoing coronary artery bypass grafting, and cardiovascular mortality. In a meta-analysis of eight cohort studies with patients undergoing myocardial revascularization or coronaryography, a high NLR increased about twice the risk of cardiovascular and all-cause mortality.

**The NLR as a biomarker in cerebrovascular disease**

In patients with stroke, the NLR is an independent mortality predictor in the short and long term. An NLR ≥5.9 at admission was associated with significant functional dependence (OR 6.72, \( P=0.0025 \)) and predicted mortality at 90 days (OR 6.69, \( P=0.006 \)) after adjusting for potential confounders. In those patients with ischemic stroke who underwent carotid ultrasonography, NLR significantly predicted the degree of carotid stenosis in male patients.

In a study in Turkey with patients who presented to the emergency service with cerebrovascular accident (stroke and transient ischemic attack), the NLR was significantly higher in patients who died (\( P<0.001 \)) and in those with ischemic or hemorrhagic stroke than in those with transient ischemic attack (\( P<0.001 \)).

**The NLR as a biomarker in other vascular diseases**

The role of NLR seems to begin even before the occurrence of any target organ damage, as was demonstrated in a cohort in which a higher NLR level significantly correlated with an increased risk of developing hypertension compared to participants with lower levels (OR 1.23; 95% confidence interval [CI] 1.06, 1.43). In other studies in hypertension, patients with nondipper pattern (that is associated with cardiovascular mortality) presented significantly higher mean NLR than those with dipper pattern (3.1±0.95 vs 1.8±0.52, \( P<0.001 \)). NLR is also associated with resistant hypertension and other risk factors for atherosclerosis such as metabolic syndrome and diabetes. Table 1 summarizes the clinical studies on the predictive value of inflammatory biomarkers in cardiovascular outcomes.

**Inflammatory markers in PAD**

Several studies have demonstrated the association between inflammatory markers and the incidence, severity, response to treatment, and prognosis of PAD. CRP was, in a cohort, the strongest nonlipidic predictor of PAD (relative risk [RR] 2.8 for the highest quartile in comparison to the lowest). In other studies, the CRP was a significant predictor of major adverse limb events (target vessel revascularization, amputation, or disease progression) and major cardiovascular events in patients with PAD who have undergone angioplasty or stent and a predictor of mortality.

In patients being treated with statins for PAD, the benefit of reducing mortality from all causes and CVD was only significant in those with baseline CRP above the median and not in those with baseline CRP below the median.
Table 1 Clinical studies on the predictive value of inflammatory biomarkers in various cardiovascular outcomes other than PAD

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Marker</th>
<th>Patients and/or type of CVE</th>
<th>Threshold</th>
<th>Assessment period</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chia et al&lt;sup&gt;79&lt;/sup&gt;</td>
<td>2009</td>
<td>Total leukocyte and neutrophil counts</td>
<td>STEMI</td>
<td>Leukocyte: &gt;10,800/mm&lt;sup&gt;3&lt;/sup&gt; and neutrophil: &gt;8,000/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>24 hours before and 1 day, 2 days, 3 days, 5 days, and 30 days after PCI</td>
<td>Elevated leukocyte and neutrophil counts after primary PCI were directly related to myocardial infarct size, decreased LveF, and independently predicted cardiovascular outcomes. In multivariate analyses, hs-CRP was the only inflammatory marker that independently predicted the risk of CVE. Patients in the highest hs-CRP quartiles had significantly higher risk compared to those in the lowest.</td>
</tr>
<tr>
<td>Ridker et al&lt;sup&gt;24&lt;/sup&gt;</td>
<td>2000</td>
<td>hs-CRP, IL-6, and others</td>
<td>28,263 apparently healthy postmenopausal women</td>
<td>hs-CRP: 0.85 mg/dL; IL-6: 2.7 pg/mL</td>
<td>At baseline</td>
<td>The highest NLR tertile was an independent predictor of cardiac mortality in patients with stable CAD.</td>
</tr>
<tr>
<td>Hong et al&lt;sup&gt;80&lt;/sup&gt;</td>
<td>2006</td>
<td>hs-CRP</td>
<td>Patients with angiographically significant coronary artery stenosis</td>
<td>0.5 mg/dL</td>
<td>Before stent implantation</td>
<td>In patients with soft plaque, an elevated hs-CRP level was significantly associated with ISR.</td>
</tr>
<tr>
<td>Papa et al&lt;sup&gt;19&lt;/sup&gt;</td>
<td>2008</td>
<td>NLR</td>
<td>Patients with angiographically documented CAD</td>
<td>Multiple cutoffs (≤1.62, 1.63–2.5, and &gt;2.55)</td>
<td>At baseline</td>
<td>A high NLR value (&gt;3) was an independent predictor of CAD severity and predictor of worse clinical outcome.</td>
</tr>
<tr>
<td>Arbel et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>2012</td>
<td>NLR</td>
<td>Patients undergoing coronary angiography for various indications</td>
<td>Multiple cutoffs (&lt;2, 2–3, and &gt;3)</td>
<td>At the time of coronary angiography procedure</td>
<td>A higher NLR (&gt;6.5) was independently associated with lower ejection fraction and higher mortality rates up to 5 years. A high NLR (&gt;4.7) was an independent predictor of short- and long-term mortality. A higher NLR (&gt;7.35) was associated with increased mortality in patients with ICH.</td>
</tr>
<tr>
<td>Arbel et al&lt;sup&gt;19&lt;/sup&gt;</td>
<td>2014</td>
<td>NLR</td>
<td>STEMI</td>
<td>6.5</td>
<td>At the time of coronary angiography procedure</td>
<td>A higher NLR (&gt;6.5) was independently associated with lower ejection fraction and higher mortality rates up to 5 years. A high NLR (&gt;4.7) was an independent predictor of short- and long-term mortality. A higher NLR (&gt;7.35) was associated with increased mortality in patients with ICH.</td>
</tr>
<tr>
<td>Azab et al&lt;sup&gt;28&lt;/sup&gt;</td>
<td>2010</td>
<td>NLR</td>
<td>NSTE-MI</td>
<td>Multiple cutoffs (&lt;3, 3–4.7, and &gt;4.7)</td>
<td>At admission</td>
<td>A higher NLR (&gt;6.5) was independently associated with lower ejection fraction and higher mortality rates up to 5 years. A high NLR (&gt;4.7) was an independent predictor of short- and long-term mortality. A higher NLR (&gt;7.35) was associated with increased mortality in patients with ICH.</td>
</tr>
<tr>
<td>Wang et al&lt;sup&gt;35&lt;/sup&gt;</td>
<td>2016</td>
<td>NLR</td>
<td>ICH</td>
<td>7.35</td>
<td>At admission and next morning</td>
<td>A higher NLR (&gt;6.5) was independently associated with lower ejection fraction and higher mortality rates up to 5 years. A high NLR (&gt;4.7) was an independent predictor of short- and long-term mortality. A higher NLR (&gt;7.35) was associated with increased mortality in patients with ICH.</td>
</tr>
<tr>
<td>Misumida et al&lt;sup&gt;81&lt;/sup&gt;</td>
<td>2015</td>
<td>NLR</td>
<td>NSTE-MI</td>
<td>2.8</td>
<td>At admission</td>
<td>A higher NLR (&gt;6.5) was independently associated with lower ejection fraction and higher mortality rates up to 5 years. A high NLR (&gt;4.7) was an independent predictor of short- and long-term mortality. A higher NLR (&gt;7.35) was associated with increased mortality in patients with ICH.</td>
</tr>
<tr>
<td>Belen et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>2015</td>
<td>NLR</td>
<td>Resistant hypertension</td>
<td>Multiple cutoffs (1.87, 2.11, and 3.15)</td>
<td>During data collection</td>
<td>Patients with resistant hypertension had significantly higher NLR (3.15) than those with controlled hypertension or normotensives.</td>
</tr>
<tr>
<td>Duffy et al&lt;sup&gt;42&lt;/sup&gt;</td>
<td>2006</td>
<td>NLR</td>
<td>Patients undergoing PCI</td>
<td>Multiple cutoffs (1.7, 3.2, and 11.2)</td>
<td>Before the procedure</td>
<td>Patients in higher tertiles of NLR (11.2) had increased risk of long-term mortality, regardless the reason of the PCI indication.</td>
</tr>
<tr>
<td>Núñez et al&lt;sup&gt;83&lt;/sup&gt;</td>
<td>2008</td>
<td>NLR</td>
<td>STEMI</td>
<td>Multiple cutoffs (quintiles)</td>
<td>At admission and daily for the first 96 hours</td>
<td>Patients in higher quintiles of NLR (fourth and fifth) presented the highest mortality risk.</td>
</tr>
<tr>
<td>Kaya et al&lt;sup&gt;84&lt;/sup&gt;</td>
<td>2013</td>
<td>NLR</td>
<td>STEMI</td>
<td>Multiple cutoffs (&lt;2.3, 2.3–4.4, and &gt;4.4)</td>
<td>At admission</td>
<td>A higher tertile of NLR (&gt;2.3) was an independent predictor of both in-hospital and long-term thrombosis, nonfatal myocardial infarction, and cardiovascular mortality.</td>
</tr>
<tr>
<td>Tokgoz et al&lt;sup&gt;85&lt;/sup&gt;</td>
<td>2013</td>
<td>NLR</td>
<td>Acute stroke</td>
<td>5</td>
<td>At admission</td>
<td>NLR &gt;5.0 was a predictor of short-term mortality in acute stroke patients.</td>
</tr>
<tr>
<td>Tokgoz et al&lt;sup&gt;84&lt;/sup&gt;</td>
<td>2014</td>
<td>NLR</td>
<td>AIS</td>
<td>4.81</td>
<td>At admission</td>
<td>NLR &gt;4.81 at the time of hospital admission was a predictor of short-term mortality, independent of the volume of infarct.</td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Marker</th>
<th>Patients and/or type of CVE</th>
<th>Threshold</th>
<th>Assessment period</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyun et al[37]</td>
<td>2015</td>
<td>NLR</td>
<td>Patients with acute to subacute ischemic stroke</td>
<td>Mean comparison between groups according to carotid IMT</td>
<td>At admission</td>
<td>Mean NLR was significantly higher among male patients with high carotid IMT compared to those with low IMT (3.9 vs 2.65).</td>
</tr>
<tr>
<td>Ertaş et al[40]</td>
<td>2013</td>
<td>NLR</td>
<td>Patients with nonvalvar atrial fibrillation</td>
<td>Mean comparison among subjects with or without stroke</td>
<td>At admission</td>
<td>Mean NLR was significantly higher among subjects with stroke compared to those without (5.6 vs 3.1).</td>
</tr>
<tr>
<td>Brooks et al[36]</td>
<td>2014</td>
<td>NLR</td>
<td>AIS</td>
<td>5.9</td>
<td>At admission</td>
<td>A higher NLR (≥5.9) predicted poor outcome and death at 90 days after endovascular stroke therapy.</td>
</tr>
<tr>
<td>Taşoğlu et al[31]</td>
<td>2014</td>
<td>NLR</td>
<td>Patients undergoing CABG surgery</td>
<td>Multiple cutoffs (1.69, 2.55, and 3.80)</td>
<td>Preprocedural</td>
<td>A high preoperative NLR was an independent predictor of saphenous vein graft failure in those undergoing CABG.</td>
</tr>
<tr>
<td>Balli et al[37]</td>
<td>2015</td>
<td>NLR</td>
<td>Patients who underwent PCI for bifurcation lesions</td>
<td>3.43</td>
<td>Before and after PCI intervention</td>
<td>A high NLR (&gt;3.43) was an independent predictor of ISR in patients who underwent bifurcation PCI.</td>
</tr>
<tr>
<td>Cho et al[38]^a</td>
<td>2015</td>
<td>NLR</td>
<td>Angina and NSTeMi</td>
<td>2.6</td>
<td>Before PCI</td>
<td>A high NLR (&gt;2.6) was an independent predictor of long-term adverse clinical outcomes such as all-cause mortality, cardiac death, and myocardial infarction.</td>
</tr>
<tr>
<td>Park et al[39]</td>
<td>2013</td>
<td>NLR</td>
<td>STEMI</td>
<td>Multiple cutoffs (1.4, 1.5–1.9, 2.0–2.4, and ≥2.5)</td>
<td>After 12 hours fast</td>
<td>A higher NLR (≥2.5) was independently associated with arterial stiffness and CCS.</td>
</tr>
<tr>
<td>Shah et al[37]</td>
<td>2014</td>
<td>NLR</td>
<td>Asymptomatic, apparently healthy individuals, from NHANES-III</td>
<td>Multiple cutoffs (&lt;1.5, 1.5–&lt;3, 3–4.5, and ≥4.5)</td>
<td>At NHANES-III data collection time</td>
<td>A high NLR (&gt;4.5) was an independent predictor of CHD mortality and improved marginally the Framingham risk score in prediction of CHD mortality.</td>
</tr>
</tbody>
</table>

Abbreviations: AIS, acute ischemic stroke; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCS, coronary calcium score; CHD, coronary heart disease; CVE, cardiovascular events; hs-CRP, high-sensitive C-reactive protein; ICH, intracerebral hemorrhage; IL-6, interleukin-6; IMT, intima–media thickening; ISR, in-stent restenosis; LM/3vD, left main and/or three-vessel disease; LVEF, left ventricular ejection fraction; NHANES-III, National Health and Nutrition Examination Survey-III; NLR, neutrophil-lymphocyte ratio; NSTeMi, non-ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
This result suggests that the benefit of statin is closely related to their anti-inflammatory effect, which is in accordance with the findings in patients with CAD, in which the benefit of statins in survival occurs mainly in subjects with high initial CRP, with fall during treatment, independent of lipid level.\(^{49,50}\) It has also been evident in the finding that statin mitigated plaque inflammation, measured by noninvasive imaging with 18F-fluorodeoxyglucose positron emission tomography.\(^{31,52}\) And, even in apparently healthy individuals, with elevated baseline high-sensitive CRP, treatment with statin reduced significantly the incidence of major cardiovascular events.\(^{53}\)

Another inflammatory marker associated with PAD and its progression is the IL-6.\(^{46,54}\) In a cohort of 12 years of follow-up, IL-6 was the inflammatory marker that showed the strongest and consistent predictive value for progression of PAD.\(^{54}\) And, in patients with established PAD, persistently high IL-6 levels are associated with faster functional decline\(^{25}\) and greater severity of disease with critical limb ischemia (CLI).\(^{46}\) Table 2 summarizes the clinical studies on the predictive value of general inflammatory biomarkers (other than NLR) in PAD.

## The particular role of NLR as a prognostic marker in PAD

### PAD severity

In PAD, a high NLR is associated with increased severity of disease,\(^{55,56}\) as was evident in a retrospective cohort of 2,121 patients with PAD in which CLI occurred significantly more in the group with a high NLR (48.5% vs 24.3%, \(P<0.001\)).\(^{56}\) In another study including 1,995 patients with PAD, the increase in NLR was associated with a significant increase in CLI rates (20.4%, 26.1%, and 36.1% for the first, second, and third tertiles, respectively).\(^{35}\)

### Response to treatment and prognosis

In patients who initially received conservative therapy for CLI, a high NLR was an independent predictive factor for amputation and was associated with lower amputation-free survival.\(^{57,58}\) A high NLR was a risk factor for amputation within 30 days in patients who underwent initial embolectomy for acute limb ischemia\(^{31}\) and an independent predictor of graft failure (occlusion or ipsilateral amputation) in those undergoing infragastrual bypass grafting.\(^{39}\)

### Mortality

A high NLR not only predicts disease severity and response to treatment but also is a predictor of mortality.\(^{60}\) In patients followed for PAD, a high NLR predicted independently long-term cardiovascular mortality (HR 2.04, \(P=0.004\)).\(^{60}\) A high NLR at admission for chronic CLI is associated with increased mortality.\(^{61}\)

In treated patients, a high pre-intervention NLR was an independent predictor of mortality in those who have undergone infrapopliteal percutaneous intervention for CLI (HR 1.95, \(P<0.03\)).\(^{62}\) And, even in those undergoing elective revascularization, a high preoperative NLR was independently associated with increased mortality.\(^{63,64}\) Table 3 summarizes the clinical studies that have assessed the role of NLR as a prognostic biomarker in PAD.

### Potential mechanism underlying NLR role in PAD and atherosclerosis in general

Despite substantial epidemiological evidence of the predictive role of NLR in atherosclerotic manifestations, there is a lack of pathophysiological body for such findings. This derived marker is an imbalance of inflammatory cells (disproportionate dominance of neutrophils over lymphocytes), and it may be a reflection of a deeper imbalance in the immunologic response, with the dominance of effectors cells over the regulatory cells, mainly CD4\(^+\) T-helper cells.\(^{65,66}\) Some studies have described the domain of subtype T-helper 17 over the regulatory T-cells, resulting in the activation of the interleukin-17 axis that is in turn associated with vascular dysfunction, progression of atherosclerosis, and vascular events.\(^{65,67,68}\) Several other mechanisms may be involved in the link between NLR and atherosclerosis, including endothelial dysfunction\(^ {69,70}\) and oxidative stress.\(^ {71}\) However, in light of the current literature, there are no sufficient data to support the formulation of a conceptual or pathophysiology model linking the two. Despite this gap, we know that atherosclerosis is mainly an inflammatory disease,\(^ {72}\) and currently effective therapies, particularly statins, are associated with decreasing inflammatory response.\(^ {49,51,52,73}\) The most accurate understanding of the mechanisms underlying this emerging evidence from clinical studies should be a substrate of a call to action for future studies in basic science, translational, experimental, and clinical levels.

### Concerns and limitations of the NLR as a cardiovascular biomarker

Some concerns arise regarding the potential use of NLR as a cardiovascular biomarker. NLR is increased in other situations such as nonalcoholic fatty liver disease, metabolic syndrome, psoriasis, and cancer.\(^ {42,74,75}\) All these conditions share in common an inflammatory or immune response in a given point of their pathogenesis, and interestingly, most of these have been also associated with CVDs as described
Table 2 Clinical studies on the predictive value of inflammatory biomarkers (other than NLR) in PAD

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Marker</th>
<th>Number of patients</th>
<th>Threshold</th>
<th>Assessment period</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tzoulaki et al⁴⁴</td>
<td>2005</td>
<td>CRP, IL-6, and ICAM-1</td>
<td>1,592 subjects</td>
<td>Multiple cutoffs in tertiles</td>
<td>At baseline, 5 years, and 12 years</td>
<td>Higher plasma levels of CRP were associated with increasing severity of PAD, and CRP, IL-6, and ICAM-1 were associated with atherosclerosis and its progression.</td>
</tr>
<tr>
<td>Haumer et al⁰⁰</td>
<td>2005</td>
<td>Total neutrophil count</td>
<td>398 patients</td>
<td>Multiple cutoffs in tertiles</td>
<td>At baseline</td>
<td>Patients with neutrophil counts in upper tertile exhibited an increased risk for all MACE, death, and the composite of myocardial infarction, stroke, and death, compared to those in the lower tertiles.</td>
</tr>
<tr>
<td>Beckman et al⁹¹</td>
<td>2005</td>
<td>CRP</td>
<td>110 patients</td>
<td>Mean comparison between subjects with or without PAD</td>
<td>At baseline</td>
<td>CRP was significantly higher in subjects who had PAD (3.83 vs 2.11). Patients with both decreasing ABI and increasing CRP had the highest risk for hard events (myocardial infarction, stroke, and death).</td>
</tr>
<tr>
<td>Bleda et al⁹²</td>
<td>2013</td>
<td>hs-CRP</td>
<td>143 patients (85 diabetic and 58 nondiabetic) who underwent EVP</td>
<td>Mean comparison between tertiles (11.8 vs 4.3 mg/L)</td>
<td>Before the procedure</td>
<td>High basal hs-CRP, but not diabetes, was associated with incidence of reintervention and mortality during post EVP follow-up period.</td>
</tr>
<tr>
<td>Stone et al⁷⁷</td>
<td>2014</td>
<td>hs-CRP</td>
<td>118 patients who underwent elective angioplasty or stent placement</td>
<td>0.8 mg/dL</td>
<td>Before the intervention</td>
<td>Elevated preprocedural hs-CRP (&gt;0.80) was a predictor of MALE and MACE by 2 years.</td>
</tr>
<tr>
<td>Bleda et al⁹³</td>
<td>2015</td>
<td>CRP</td>
<td>121 patients undergoing EVP</td>
<td>9.8 mg/dL</td>
<td>Before the procedure</td>
<td>High baseline CRP (&gt;9.8) increased risk of EVT failure and the necessity of reintervention at first year.</td>
</tr>
<tr>
<td>Owens et al⁴⁵</td>
<td>2007</td>
<td>hs-CRP</td>
<td>Patients undergoing lower extremity bypass</td>
<td>5 mg/L</td>
<td>On the morning of lower extremity bypass</td>
<td>Elevated hs-CRP (&gt;5 mg/L) was correlated with CLI at presentation and adverse postoperative graft-related or cardiovascular events.</td>
</tr>
<tr>
<td>De Haro et al⁹⁵</td>
<td>2009</td>
<td>CRP</td>
<td>330 patients diagnosed with PAD</td>
<td>Median comparison among the three clinical severity groups</td>
<td>At the study data collection time</td>
<td>The clinical severity of PAD increased significantly with higher plasma CRP levels (median 3.8, 8.33, and 12.83 mg/L for mild, moderate, and severe disease, respectively).</td>
</tr>
<tr>
<td>Hoegh et al⁶⁶</td>
<td>2008</td>
<td>hs-CRP</td>
<td>452 patients with symptomatic PAD</td>
<td>10 mg/L</td>
<td>At study baseline</td>
<td>The baseline level of hs-CRP was significantly higher among those who developed primary end point (death or amputation) and those who developed an overall secondary end point (lower limb thrombosis, myocardial infarction, or stroke).</td>
</tr>
<tr>
<td>Lin et al⁸⁷</td>
<td>2010</td>
<td>CRP</td>
<td>85 diabetic patients with PAD and infected foot ulcers who underwent PTA</td>
<td>50 mg/L</td>
<td>Before PTA</td>
<td>Higher level of CRP was associated with major amputation after initial PTA.</td>
</tr>
<tr>
<td>McDermott et al⁹⁸</td>
<td>2006</td>
<td>hs-CRP</td>
<td>487 subjects (296 with and 191 without PAD)</td>
<td>NA (continuous)</td>
<td>At baseline and annually for 3 years</td>
<td>Greater annual increases in hs-CRP were predictors of greater functional decline during the subsequent year in patients with PAD and may reflect functional decline during the past year in subjects without PAD. The prevalence of PAD was higher among subjects in the highest CRP quartiles compared to those in the lowest (OR 6.38, P 0.005). This association persisted even after subgroup analysis by sex, age, education, smoking, and body mass index.</td>
</tr>
<tr>
<td>Shankar et al⁹⁹</td>
<td>2007</td>
<td>CRP</td>
<td>1,611 subjects without traditional risk factors for PAD (CVD, diabetes, and hypertension)</td>
<td>Multiple cutoffs (quartiles)</td>
<td>At the study data collection time</td>
<td>Higher hs-CRP tertiles at baseline were significantly associated with decreased ABI at baseline and at 12 months, reflecting severity. Furthermore, serum hs-CRP was associated with death and/or any cardiovascular event during a median 24-month follow-up period.</td>
</tr>
<tr>
<td>Vainas et al⁴⁰</td>
<td>2005</td>
<td>hs-CRP</td>
<td>387 patients with PAD</td>
<td>Multiple cutoffs (tertiles)</td>
<td>During baseline assessment</td>
<td>Higher hs-CRP tertiles at baseline were significantly associated with decreased ABI at baseline and at 12 months, reflecting severity. Furthermore, serum hs-CRP was associated with death and/or any cardiovascular event during a median 24-month follow-up period.</td>
</tr>
</tbody>
</table>

Abbreviations: ABI, ankle–brachial index; ABPI, ankle–brachial pressure index; CLI, critical limb ischemia; CRP, C-reactive protein; CVD, cardiovascular disease; EVT, endovascular therapy; hs-CRP, high-sensitive C-reactive protein; ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin-6; MALE, major adverse limb events (femoropopliteal interventions); NA, not applicable; NLR, neutrophil–lymphocyte ratio; OR, odds ratio; PAD, peripheral arterial disease; PTA, percutaneous transluminal angioplasty.
by Ganzetti et al in his recent review. Despite being a non-specific marker, NLR has shown consistency in predicting outcomes in atherosclerotic diseases, and even in the nationally representative sample of American subjects, NLR was significantly higher in those who reported diabetes, CVD, and smoking than in subjects who did not. In addition, NLR has a good correlation with other inflammatory markers such as CRP, presenting even better performance as a biomarker in specific conditions.

There are some important limitations of this study. The first is the use of different cutoff values in different studies and the scarcity of published works validating the normality value in the general population. However, as we just underlined, most studies in atherosclerosis found a higher cutoff than the average NLR value (2.15) found in the only existing study in the general population, which suggests the plausibility of the association found in those studies. The second is the absence of studies that have validated the normality value for specific populations. This point is critical because as a derived ratio, it is, of course, affected by changes either in the numerator or the denominator. For example, subjects who have a relative constitutional lymphopenia would easily be classified as having a high NLR, without necessarily an increased inflammatory activity. So, it is prone to potential bias that could lead to false-positive associations. The third is relative to the paucity of studies clarifying the mechanisms underlying the association between NLR and atherosclerosis.

Conclusion and future directions

From the available evidence, it is very likely that the presence of a high NLR has predictive value for future vascular events in asymptomatic and symptomatic subjects. This simple, fast, and widely available biomarker can offer an additional noninvasive tool for risk stratification to assess the severity, response to treatment and prognosis of PAD.

More studies are necessary to know and clarify the role of NLR as an additional tool in PAD. This is reinforced because its role has been reproducible and consistent in other vascular beds as cerebral and coronary, especially in the current scenario of growing recognition of various diseases, with chronic inflammatory component as risk factors for atherosclerosis.

Further studies should be addressed to establish the normality value for specific populations to clarify the underlying mechanisms in atherogenesis and should be designed to

### Table 3 Clinical studies on the role of NLR as prognostic biomarkers in PAD

<table>
<thead>
<tr>
<th>Study</th>
<th>Year (Number of patients)</th>
<th>Threshold</th>
<th>Assessment period</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taşoğlu et al51</td>
<td>2014 (254)</td>
<td>5.2</td>
<td>At admission</td>
<td>A higher NLR (≥5.2) was a risk factor for amputation within 30 days after surgery in patients who underwent embolectomy for acute limb ischemia.</td>
</tr>
<tr>
<td>Kullar et al39</td>
<td>2012 (126)</td>
<td>NA</td>
<td>Postoperative</td>
<td>A higher NLR was an independent predictor of graft failure (occlusion or ipsilateral amputation) after infrapopliteal bypass grafting.</td>
</tr>
<tr>
<td>Belaj et al35</td>
<td>2015 (1,995)</td>
<td>2.5</td>
<td>At the study data collection time</td>
<td>Increased rate of CLI was observed with increasing NLR tertiles (20.4%, 26.1%, and 36.1% for the lowest, second, and third tertiles, respectively).</td>
</tr>
<tr>
<td>Spark et al41</td>
<td>2010 (149)</td>
<td>5.25</td>
<td>At admission</td>
<td>A higher NLR (≥5.25) was independently associated with shorter survival in patients being treated for CLI.</td>
</tr>
<tr>
<td>Erturk et al60</td>
<td>2014 (593)</td>
<td>3</td>
<td>At the study data collection time</td>
<td>A higher NLR (&gt;3) was found to predict independently long-term cardiovascular mortality in patients with intermittent claudication and CLI.</td>
</tr>
<tr>
<td>González-Fajardo et al3</td>
<td>2014 (561)</td>
<td>5</td>
<td>At admission</td>
<td>A higher NLR (&gt;5) was associated with higher 5-year mortality and lower AFS in patients with chronic CLI who underwent elective infrapopliteal open or endovascular revascularization.</td>
</tr>
<tr>
<td>Taşoğlu et al58</td>
<td>2014 (104)</td>
<td>3.2</td>
<td>At admission</td>
<td>A higher NLR (≥3.2) was a good predictor of lower overall limb survival in patients with non-reconstructable CLI.</td>
</tr>
<tr>
<td>Chan et al32</td>
<td>2014 (83)</td>
<td>5.25</td>
<td>Before the procedure</td>
<td>Patients with a higher NLR (≥5.25) had an increased risk of death after infrapopliteal percutaneous angioplasty.</td>
</tr>
<tr>
<td>Bhutta et al64</td>
<td>2011 (1,021)</td>
<td>5</td>
<td>Before the surgery</td>
<td>A high preoperative NLR (≥5) was independently associated with mortality (OR 2.21) within 2 years after elective major vascular surgery.</td>
</tr>
<tr>
<td>Gary et al66</td>
<td>2013 (2,121)</td>
<td>3.95</td>
<td>At admission</td>
<td>In patients with PAOD, an increased NLR (&gt;3.95) was significantly associated with CLI and other vascular endpoints (myocardial infarction and stroke).</td>
</tr>
<tr>
<td>Luo et al67</td>
<td>2015 (172)</td>
<td>3.8</td>
<td>Posttreatment</td>
<td>A higher NLR (≥3.8), the posttreatment NLR, was identified as an independent predictive factor for amputation in patients who receive first conservative therapy.</td>
</tr>
</tbody>
</table>

**Abbreviations:** AFS, amputation-free survival; CLI, critical limb ischemia; NA, not applicable; NLR, neutrophil–lymphocyte ratio; OR, odds ratio; PAD, peripheral arterial disease; PAOD, peripheral arterial occlusive disease.
assess the effectiveness of anti-inflammatory therapies using the fall of NLR as a surrogate outcome and assess its role to guide therapy.

Disclosure

The authors report no conflicts of interest in this work.

References


